At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
RMC-4630 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
In Brief
A Phase 2 clinical trial evaluating RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer. Completed, enrolled 47 participants across 60 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Canada, France, Germany, Italy, South Korea, Spain, Taiwan, United Kingdom, United States
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartDec 2021
Primary CompletionJul 2024
Study CompletionAug 2024
TodayJul 2026
First PostedSep 23, 2021
Enrollment StartDec 30, 2021
Primary CompletionJul 3, 2024
Study CompletionAug 29, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.8 years ago
Interventions
RMC-4630drug
RMC-4630 administered orally as a capsule
Sotorasibdrug
Sotorasib administered orally as a tablet